Quantcast
Skip to main content
Department of Neurology

Department of Neurology

Faculty | Professors

RELATED RESOURCES

Subspecialties:
Movement disorders, Parkinson's disease 

 

E-mail:
lin.zhang@ucdmc.ucdavis.edu

 

Appointments:
To see if Lin Zhang is accepting new patients, or for assistance finding a UC Davis doctor, please call (800) 2-UC DAVIS.

Lin Zhang, M.D., Ph.D.

Lin Zhang, M.D., Ph.D.

Associate Professor
Director of Movement Disorders Program,
Sacramento VA Medical Center, NCVAHS
Director of Neurotoxin (Botox) Therapeutics Program
Specialty: Neurology

Lawrence J. Ellison Ambulatory Care Center
4860 Y St., Suite 0100
Sacramento, CA 95817
(916) 734-3588

Clinical & Research Interests

Dr. Zhang's clinical and research interests focus primarily on Parkinson's disease, including its epidemiology and the association between past nutritional deficiency and current prevalence of the disease. He is testing new drugs with neuroprotective properties that may slow down the progression of Parkinson's. He also is investigating the clinical manifestation of the disease in patients with atypical Parkinson's disease, and those with a family history of pre-mutation for fragile X syndrome, a genetic disorder that typically affects children.

 

Additionally, Dr. Zhang specializes in botulinum toxin (Botox) treatments for a variety of conditions, including, but not limited to, dystonia, spasticity and tremor. He uses electric muscle testing when giving Botox injections to improve accuracy and gain maximal results.

Other Languages

Chinese

Education

Beijing University School of Medicine
Beijing, China
M.D. 1984


Tulane University
New Orleans, Louisiana
Ph.D. 1994

Internships

Cleveland Clinic Foundation
Cleveland, Ohio
1994-1995

 

Beijing Hospital
Beijing, China
1983-1985
Internal Medicine

 

Residency

Cleveland Clinic Foundation
Cleveland, Ohio
1995-1998
Neurology

 

Beijing Hospital
Beijing, China
1983-1985
Internal Medicine

Fellowships

University of Rochester
Rochester, New York
1998-2000
Movement Disorders & Experimental Therapeutics

Professional Memberships

American Academy of Neurology

Select Recent Publications

D.A.Hall, E. Berry-Kreavis, S Jacquemont, C.D. Rice, J. Cogwell, L. Zhang et al (2005): Misdiagnosis of Fragile X associated Tremor/Ataxia Syndrome (FXTAS). Neurology.


JA. Bourgeois, F. Farzin, J.A. Brunberg, F. Fassone, P. Hagerman, L. Zhang et al (2005): Dementia with Mood Symptoms in a Carrier of the Fragile X associated Tremor/Ataxia Syndrome (FXTAS): Clinical Intervention with Donepezil and Venlafaxine. J. Clinical psychology and Neurosciences


L. Ma, L. Zhang, XH. Gao, W. Chen, et al (2005): Dietary Factors and Smoking as Risk Factors for PD in a Rural Population in China: A nested Case Control Study. Acta Neurologica Scandinavica


DF. Zhou, YL Qiao, P. Como, K. Kieburtz, L Zhang (2005): The Prevalence of Dementia in Rural China: the Impact of Age, Gender and Education. Acta neurologica Scandinavica.


Lin Zhang, Z.Y. Nie, Y Liu, K. Kieburtz. (2005): the Prevalence of PD in a Nutritionally Deficient Rural Population in China. Acta Neurologica Scandinavica 112(1):29-35.


Jacquemont S, Farzin F, Hall DA, Leehey MA, Tassone F, Gane LW, Zhang L, et al. (2004): Aging in individuals with the FMR1 mutation. Am J Ment Retard 109(2): 154-164.


Jacquemont S, Hagerman R, Leehey M, Greco C, Brunberg J, Tassone F, Gane L, Jardini T, Harris S, Zhang L, et al. (2004): A New Progressive Neurological Condition in Older Adult Male Carriers of the Fragile X Premutation: Clinical, Neuroimaging and Molecular Data on 20 Patients, and Epidemiological Studies. Am J. Hum Genet.


Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco C, Brunberg J, Tasone F, Hessl D, Harris SW, Zhang L, et al (2004): Fragile X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 74: 1051-1056.


Hagerman RJ, Leavitt BR, Farzin F, Jacquemont S, Greco C, Brunberg J, Tasone F, Hessl D, Harris SW, Zhang L, et al (2004): Prevalence of the fragile X-associated tremor/ataxia syndrome (FXTAS) in a premutation carrier population. JAMA 291(4): 460-469.


Parkinson Study Group (2003): A controlled trial of rotigotine Monotherapy In Early Parkinson's Disease (PATCH study). Arch. Neuro 60(12): 1721-8.